Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss

NCT06909123 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT06909123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06909123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Withdrawn
Start date
July 31, 2026
Completion date
July 31, 2027
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lactation suppressed